Key Figures Q1 2021

SEK m, unless otherwise stated

2021

Jan-Mar

2020

Jan-Mar

2020

Jan-Dec

2020-2021

Jan-Mar Δ

Net revenues

132.3

175.0

663.6

-24%

Cost of goods sold

-19.2

-20.0

-65.6

-4%

Operating expenses

-149.9

-121.1

-617.9

24%

EBIT

-36.8

34.0

-19.9

-208%

EBIT margin, %

-27.8

19.4

-3.0

-47.2 ppt

EBITDA

23.9

39.1

19.0

-161%

Earnings per share, before dilution, SEK

-0.92

2.38

-2.45

-139%

Earnings per share, after dilution, SEK

-0.92

2.34

-2.45

-139%

Cash flow from operating activities

-47.8

48.1

16.8

-199%

Cash and cash equivalents

725.5

861.4

505.3

-16%

Net revenues and EBIT per segment Q1 2021

SEK m

Net Revenues

EBIT

 

2021 Jan-Mar

2020 Jan-Mar

2020 Jan-Dec

2021 Jan-Mar

2020 Jan-Mar

2020 Jan-Dec

ZUBSOLV® US

126.8

163.9

623.3

-

-

-

US Pharma – total

126.8

163.9

623.3

66.1

75.9

331.2

Digital Therapeutics (DTx) product sales

0.2

-

0.0

-

-

-

Digital Therapeutics (DTx) – total

0.2

-

0.0

-58.7

-12.1

-175.4

Abstral® royalties

2.7

8.6

29.7

-

-

-

Edluar® royalties

2.6

2.4

10.4

-

-

-

ZUBSOLV® - ex US

-

0.1

0.1

-

-

-

OX-MPI

-

-

-

-

-

-

HQ & Pipeline

segment – total

5.3

11.1

40.2

-44.2

-29.9

-175.8

Total

132.3

175.0

663.6

-36.8

34.0

-19.9


Cash flow Q1 2021

 

SEK m

2021

Jan-Mar

2020

Jan-Mar

2020

Jan-Dec

Cash flow from operating activities

-47.8

48.1

16.8

Investment activities

-16.2

-3.9

-189.2

Financing activities

-261.7

-68.8

-111.3

Cash flow (excl exchange rate differences)

197.7

-24.6

-283.7

Liquid funds

725.5

861.4

505.3